# EDGAR Filing Document

**Accession Number:** 0000882361
**File Stem:** 0001193125-26-134870
**Filing Date:** 2026-3
**Character Count:** 6077
**Document Hash:** e402d4750dee997ea6a64611466794ef
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-134870.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0001193125-26-134870

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260331

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aptose Biosciences Inc.
- **CENTRAL INDEX KEY:** 0000882361
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32001
- **FILM NUMBER:** 26823119

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 66 WELLINGTON STREET WEST, SUITE 5300
- **STREET 2:** TD BANK TOWER BOX 48
- **CITY:** TORONTO
- **PROVINCE COUNTRY:** A6
- **BUSINESS PHONE:** 310-849-8060

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 66 WELLINGTON STREET WEST, SUITE 5300
- **STREET 2:** TD BANK TOWER BOX 48
- **CITY:** TORONTO
- **PROVINCE COUNTRY:** A6

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.)
- **DATE OF NAME CHANGE:** 20140905

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LORUS THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 19990308

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IMUTEC PHARMA INC
- **DATE OF NAME CHANGE:** 19970113

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): March 31, 2026

## APTOSE BIOSCIENCES INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Canada** | **001-32001** | **98-1136802** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification No.)** |

---

#### 66 Wellington Street West, Suite 5300

#### TD Bank Tower, Box 48

#### Toronto, Ontario M5K 1E6

#### Canada

#### (Address of Principal Executive Offices) (Zip Code)
(647) 479-9828

#### (Registrant's telephone number, including area code)

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| None | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.**  |

---

On March 31, 2026, Aptose Biosciences Inc., or the "Corporation," held its Special Meeting of the shareholders of the Corporation (the "Meeting"). At the Meeting, shareholders voted in favor of all items of business, as indicated below:

#### Proposal No. 1 – Continuance Resolution
The Corporation's shareholders voted to approve the continuation of the Corporation from the Canada Business Corporations Act ("CBCA") to the Business Corporations Act (Alberta).

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Votes For** | **% Votes For** | **Vote Against** | **% Votes Against** | **Abstain** | **Broker Non-Votes** |
| 1075838 | 92.42% | 76950 | 6.61% | 11242 | 0 |

---

#### Proposal No. 2 – Arrangement Resolution
The Corporation's shareholders voted to approve the plan of arrangement (announced on November 19, 2025 and February 24, 2026) pursuant to which HS North America Ltd. (the "Purchaser"), a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd. ("Hanmi" and together with the Purchaser, the "Hanmi Purchasers") will acquire all of the issued and outstanding common shares of the Corporation that are not currently owned or controlled by the Hanmi Purchasers or their respective affiliates.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Votes For** | **% Votes For** | **Vote Against** | **% Votes Against** | **Abstain** | **Broker Non-Votes** |
| 556154 | 84.87% | 97552 | 14.89% | 1614 | 0 |

---

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description of Exhibit** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Aptose Biosciences Inc.** | **Aptose Biosciences Inc.** |
| Date: March 31, 2026 | By: | /s/ William G. Rice, Ph.D. |
|  |  | William G. Rice, Ph.D. |
|  |  | Chairman, President, and Chief Executive Officer |

---